| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/23/2013 | EP2548889A1 Antibodies against human interleukin-13 and uses thereof |
| 01/23/2013 | EP2548888A1 Periodontal-disease-specific peptide, and treatment and diagnosis of periodontal disease using same |
| 01/23/2013 | EP2548885A2 Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system |
| 01/23/2013 | EP2548884A2 Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system |
| 01/23/2013 | EP2548583A2 Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
| 01/23/2013 | EP2548579A1 Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases |
| 01/23/2013 | EP2548578A1 Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases |
| 01/23/2013 | EP2548577A1 Human anti-il-23 antibodies, compositions, methods and uses |
| 01/23/2013 | EP2548576A1 Diagnosis of cancer using anti-desmoglein-3 antibodies |
| 01/23/2013 | EP2548575A1 Anti-CD19 antibodies that mediate ADCC for use in treating autoimmune diseases |
| 01/23/2013 | EP2548574A1 New humanized anti-cd20 monoclonal antibody |
| 01/23/2013 | EP2548573A1 Novel neutralizing immunogen (NIMIV) of Rhinovirus and its use for vaccine applications |
| 01/23/2013 | EP2548572A2 Adjuvanted tolerogens as a malaria vaccine |
| 01/23/2013 | EP2548571A1 Compositions having means for targeting at least one antigen to dendritic cells |
| 01/23/2013 | EP2547770A2 Live attenuated chimeric porcine circovirus vaccine |
| 01/23/2013 | EP2547697A1 Immune therapy |
| 01/23/2013 | EP2547695A1 Tumor vaccination involving a humoral immune response against self-proteins |
| 01/23/2013 | EP2547691A1 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers |
| 01/23/2013 | EP2547366A2 Myeloid derived suppressor cell inhibiting agents |
| 01/23/2013 | EP2547365A1 Anti-nerve growth factor (ngf) antibody compositions |
| 01/23/2013 | EP2547364A1 Peptides, conjugates and method for increasing immunogenicity of a vaccine |
| 01/23/2013 | EP2547363A2 Methods of prevention or treatment of triggered inflammatory reactions using tumor necrosis factor alpha antagonist |
| 01/23/2013 | EP2547362A1 Disrupted adenovirus-based vaccine against drugs of abuse |
| 01/23/2013 | EP2547361A1 Bacterial vaccine components from staphylococcus aureus and uses thereof |
| 01/23/2013 | EP2547360A1 System and method of preparing and storing activated mature dendritic cells |
| 01/23/2013 | EP2547359A2 Inhibitors of beta integrin-g protein alpha subunit binding interactions |
| 01/23/2013 | EP2547358A1 Method of vaccination |
| 01/23/2013 | EP2547357A1 Adjuvanted vaccines for serogroup b meningococcus |
| 01/23/2013 | EP2547328A2 Ccr7 ligand delivery and co-delivery in immunotherapy |
| 01/23/2013 | EP2261375B1 Method of preventing virus:cell fusion by inhibiting the function of the fusion initiation region in RNA viruses having class I membrane fusogenic envelope proteins |
| 01/23/2013 | CN1972958B Method of using adenoviral vectors to induce an immune response |
| 01/23/2013 | CN102892787A Radioactive metal-labeled anti-cadherin antibody |
| 01/23/2013 | CN102892784A Methods for treating breast cancer |
| 01/23/2013 | CN102892783A Method of inducing production of protective anti-hiv-1 antibodie |
| 01/23/2013 | CN102892779A Neuregulin antagonists and use thereof in treating cancer |
| 01/23/2013 | CN102892777A Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers |
| 01/23/2013 | CN102892734A Improved methods for preparing squalene |
| 01/23/2013 | CN102892432A Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis |
| 01/23/2013 | CN102892431A Peptides, conjugates and method for increasing immunogenicity of a vaccine |
| 01/23/2013 | CN102892430A Anti-nerve growth factor (ngf) antibody compositions |
| 01/23/2013 | CN102892429A Disrupted adenovirus-based vaccine against drugs of abuse |
| 01/23/2013 | CN102892428A Parapoxvirus expressing the vp60 major capsid protein of the rabbit haemorrhagic disease virus |
| 01/23/2013 | CN102892427A Excipients for stabilising viral particles, polypeptides or biological material |
| 01/23/2013 | CN102892426A Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| 01/23/2013 | CN102892424A Stabilisation of viral particles |
| 01/23/2013 | CN102892409A Method for preserving alum adjuvants and alum-adjuvanted vaccines |
| 01/23/2013 | CN102888383A Recombinant porcine pseudorabies virus TK/gE double-gene deletion strain |
| 01/23/2013 | CN102887955A Purified antibody composition |
| 01/23/2013 | CN102887954A Human anti-il-23 antibodies, compositions, methods and uses |
| 01/23/2013 | CN102887953A Anti-abeta antibodies and their use |
| 01/23/2013 | CN102886044A Nano adjuvant, influenza virus vaccine containing nana adjuvant and preparation method of influenza virus vaccine |
| 01/23/2013 | CN102886043A Binary inactivated vaccine against Japanese encephalitis virus and porcine parvovirus and preparation method thereof |
| 01/23/2013 | CN102166352B Preparation method of swine influenza bivalent inactivated vaccine and product of swine influenza bivalent inactivated vaccine |
| 01/23/2013 | CN102115729B Method for culturing baby hamster kidney (BHK) 21 cell in serum-free way, and vaccine preparation method |
| 01/23/2013 | CN102100910B Method for producing viral vaccines |
| 01/23/2013 | CN102058881B Gene recombinant vaccine for preventing enterovirus 71 infection and preparation method thereof |
| 01/23/2013 | CN102002105B Gene, expression vector, expression method, expression cell and application of human papilloma virus (HPV) 16 E7E6 fusion protein |
| 01/23/2013 | CN101687049B Immunocytokines for cancer treatment in combination with chemotherapeutic agents |
| 01/23/2013 | CN101618213B Combined attenuated live vaccine for measles, mumps and encephalitis B and preparation method thereof |
| 01/23/2013 | CN101563105B Compositions and methods for inhibiting smad4-deficient cancers |
| 01/23/2013 | CN101210244B Neutrokine-alpha and Neutrokine-alpha splice variants |
| 01/23/2013 | CN101193914B Antibodies directed against amyloid-beta peptide and methods using same |
| 01/22/2013 | US8357792 SRSV detection kit |
| 01/22/2013 | US8357791 DNA and proteins or peptides specific of bacteria of the Neisseria meningitidis species, methods for obtaining them and biological applications thereof |
| 01/22/2013 | US8357789 comprising an RNA sequence capable of specifically binding a polypeptide participating in influenza virus infection of cells |
| 01/22/2013 | US8357783 Human anti-mesothelin monoclonal antibodies |
| 01/22/2013 | US8357782 Monoclonal antibodies specific for human interferon-alpha subtype alpha 8 |
| 01/22/2013 | US8357525 Thermal inactivation of rotavirus |
| 01/22/2013 | US8357496 Method for the diagnosis or the screening of an arbovirus infection, reagents useful in said method and their applications |
| 01/22/2013 | US8357494 Anti-clusterin oligoclonal antibodies for diagnosis and prediction of the aggressiveness of tumours, diagnostic method and related kits |
| 01/22/2013 | US8357486 Methods and compositions for detection of bacteria and treatment of diseases and disorders |
| 01/22/2013 | US8357377 Drug carriers; such as nucleic acids; sustained release; biocompatibility polymer |
| 01/22/2013 | US8357376 Method of purifying influenza virus and removing MDCK cell DNA contaminants |
| 01/22/2013 | US8357375 Process for the preparation and use of a bivalent vaccine against morphine-heroine addiction |
| 01/22/2013 | US8357374 Conjugates of synthetic TLR agonists and uses therefor |
| 01/22/2013 | US8357373 Methods for stimulating an immune response using bacterial antigen delivery system |
| 01/22/2013 | US8357372 Agent for treating allergic or hypersensitivity condition |
| 01/22/2013 | US8357371 Methods for treating hypercholesterolemia using antibodies to PCSK9 |
| 01/22/2013 | US8357370 Anti-D monoclonal antibodies |
| 01/22/2013 | US8357369 Genetic markers for predicting responsiveness to combination therapy |
| 01/22/2013 | US8357368 Methods of treating pancreatic or liver cancer using hedgehog antagonists |
| 01/22/2013 | US8357367 Antibodies that bind PAR-2 |
| 01/22/2013 | US8357363 Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom |
| 01/22/2013 | CA2653939C Immunostimulatory oligonucleotides and use thereof in pharmaceuticals |
| 01/22/2013 | CA2554461C Method for obtaining precursor z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency |
| 01/22/2013 | CA2513458C Virulent systemic feline calicivirus |
| 01/22/2013 | CA2494192C Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes |
| 01/22/2013 | CA2489515C Methods and compositions for modulating and detecting wisp activity |
| 01/22/2013 | CA2483819C Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus |
| 01/22/2013 | CA2441663C Viral vectors and their use in therapeutic methods |
| 01/22/2013 | CA2425862C Cd19-specific redirected immune cells |
| 01/22/2013 | CA2411397C Reovirus for the treatment of ral-mediated cellular proliferative disorders |
| 01/22/2013 | CA2375619C Equine granulocyte-macrophage colony-stimulating factor (gm-csf) |
| 01/22/2013 | CA2329267C A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upflp, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 01/22/2013 | CA2290078C Erysipelothrix rhusiopathiae antigens and vaccine compositions |
| 01/17/2013 | WO2013010132A1 Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| 01/17/2013 | WO2013010101A1 Method of treating and reducing the risk of acute myelogenous leukemia |
| 01/17/2013 | WO2013009981A2 Treating neurological disease or injury with a dynamin-related protein 1 (drp1) encoding nucleic acid |
| 01/17/2013 | WO2013009868A1 Compositions and methods for making selenocysteine containing polypeptides |
| 01/17/2013 | WO2013009849A1 Parenteral norovirus vaccine formulations |